Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16756578 | 0.79 | TNF (0.62) | TNFTSHRNPC1MAPTTP53 | |
| SCHEMBL15560565 | 0.77 | TSHR (0.72) | TNFTSHRNPC1MAPTTP53 | |
| SCHEMBL16756579 | 0.75 | TSHR (1.00) | TNFTSHRNPC1MAPTTP53 | |
| SCHEMBL30582653 | 0.75 | TSHR (1.00) | TNFTSHRNPC1MAPTTP53 | |
| SCHEMBL15560601 | 0.74 | TSHR (0.67) | TNFTSHRNPC1MAPTTP53 | |
| SCHEMBL16756333 | 0.71 | TSHR (0.64) | TNFTSHRNPC1TP53MAPK1 | |
| SCHEMBL25655674 | 0.70 | TNF (0.52) | TNFTSHRNPC1MAPTTP53 | |
| SCHEMBL25655643 | 0.67 | NPC1 (0.36) | TSHRNPC1MAPTRAB9APOLB | |
| SCHEMBL26799668 | 0.66 | TP53 (0.47) | TNFTSHRMAPTTP53POLB | |
| SCHEMBL2018088 | 0.65 | TNF (0.53) | TNFTSHRNPC1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3311168-B1 | NOVEL TNF STRUCTURE FOR USE IN THERAPY | UCB Biopharma SRL (BE) | 2023-05-10 | — | — | EP | disclosed |
| US-20210088530-A1 | NOVEL TNFa STRUCTURE FOR USE IN THERAPY | UCB Biopharma SRL (BE) | 2021-03-25 | — | — | US | disclosed |
| US-10775385-B2 | Treatment of autoimmune and inflammatory disorders with asymmetric TNF alpha trimers | UCB Biopharma SRL (BE) | 2020-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210088530-A1 | NOVEL TNFa STRUCTURE FOR USE IN THERAPY | TNFRSF1A, TNFRSF9, CD40 | TNF 5/4885TSHR 259/4885NPC1 4061/4885 |
| US-10775385-B2 | Treatment of autoimmune and inflammatory disorders with asymmetric TNF alpha trimers | TNFRSF1A, TNFRSF9, CD40 | TNF 4/4885TSHR 218/4885NPC1 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.